United Therapeutics Corporation Net Income (Loss) Available to Common Stockholders, Basic
United Therapeutics Corporation (UTHR) reported Net Income (Loss) Available to Common Stockholders, Basic of $727.30 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-22.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2023-02-22
- United Therapeutics Corporation net income (loss) available to common stockholders, basic for the quarter ending 2020-03-31 was $137.70M.
- United Therapeutics Corporation net income (loss) available to common stockholders, basic for the quarter ending 2019-12-31 was $52.60M, a 19.45% decline year-over-year.
- United Therapeutics Corporation net income (loss) available to common stockholders, basic for the quarter ending 2019-09-30 was $132.40M, a 24.32% increase year-over-year.
- United Therapeutics Corporation net income (loss) available to common stockholders, basic for the quarter ending 2019-06-30 was $205.10M, a 18.62% increase year-over-year.
- United Therapeutics Corporation net income (loss) available to common stockholders, basic for fiscal 2022 was $727.30M, a 52.86% increase from fiscal 2021.
- United Therapeutics Corporation net income (loss) available to common stockholders, basic for fiscal 2021 was $475.80M, a 7.58% decline from fiscal 2020.
- United Therapeutics Corporation net income (loss) available to common stockholders, basic for fiscal 2020 was $514.80M.
- United Therapeutics Corporation net income (loss) available to common stockholders, basic for fiscal 2019 was -$104.50M, a 117.74% decline from fiscal 2018.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | $727.30M 10-K · filed 2023-02-22 | |||||||
| 2021-12-31 | $475.80M 10-K · filed 2023-02-22 | |||||||
| 2020-12-31 | $514.80M 10-K · filed 2023-02-22 | |||||||
| 2020-03-31 | $137.70M 10-Q · filed 2020-04-29 | $190.30M derived: sum of 2 quarters · filed 2020-04-29 | $322.70M derived: sum of 3 quarters · filed 2020-04-29 | $527.80M derived: sum of 4 quarters · filed 2020-04-29 | ||||
| 2019-12-31 | $52.60M 10-K · filed 2020-02-26 | $185.00M derived: sum of 2 quarters · filed 2020-02-26 | $390.10M derived: sum of 3 quarters · filed 2020-02-26 | -$104.50M 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | $132.40M 10-K · filed 2020-02-26 | $337.50M derived: sum of 2 quarters · filed 2020-02-26 | -$157.10M 10-Q · filed 2019-10-30 | -$91.80M derived: sum of 4 quarters · filed 2020-04-29 | ||||
| 2019-06-30 | $205.10M 10-K · filed 2020-02-26 | -$289.50M 10-Q · filed 2019-07-31 | -$224.20M derived: sum of 3 quarters · filed 2020-04-29 | -$117.70M derived: sum of 4 quarters · filed 2020-04-29 | ||||
| 2019-03-31 | -$494.60M 10-Q · filed 2020-04-29 | -$429.30M derived: sum of 2 quarters · filed 2020-04-29 | -$322.80M derived: sum of 3 quarters · filed 2020-04-29 | -$149.90M derived: sum of 4 quarters · filed 2020-04-29 | ||||
| 2018-12-31 | $65.30M 10-K · filed 2020-02-26 | $171.80M derived: sum of 2 quarters · filed 2020-02-26 | $344.70M derived: sum of 3 quarters · filed 2020-02-26 | $589.20M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | $106.50M 10-K · filed 2020-02-26 | $279.40M derived: sum of 2 quarters · filed 2020-02-26 | $523.90M 10-Q · filed 2019-10-30 | $542.90M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-06-30 | $172.90M 10-K · filed 2020-02-26 | $417.40M 10-Q · filed 2019-07-31 | $436.40M derived: sum of 3 quarters · filed 2020-02-26 | $712.70M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-03-31 | $244.50M 10-K · filed 2020-02-26 | $263.50M derived: sum of 2 quarters · filed 2020-02-26 | $539.80M derived: sum of 3 quarters · filed 2020-02-26 | $483.80M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2017-12-31 | $19.00M 10-K · filed 2019-02-27 | $295.30M derived: sum of 2 quarters · filed 2019-02-27 | $239.30M derived: sum of 3 quarters · filed 2019-02-27 | $417.90M 10-K · filed 2020-02-26 | ||||
| 2017-09-30 | $276.30M 10-K · filed 2019-02-27 | $220.30M derived: sum of 2 quarters · filed 2019-02-27 | $398.90M 10-Q · filed 2018-10-31 | $509.20M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-06-30 | -$56.00M 10-K · filed 2019-02-27 | $122.60M 10-Q · filed 2018-08-01 | $232.90M derived: sum of 3 quarters · filed 2019-02-27 | $394.70M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-03-31 | $178.60M 10-K · filed 2019-02-27 | $288.90M derived: sum of 2 quarters · filed 2019-02-27 | $450.70M derived: sum of 3 quarters · filed 2019-02-27 | $656.80M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | $110.30M 10-K · filed 2018-02-21 | $272.10M derived: sum of 2 quarters · filed 2018-02-21 | $478.20M derived: sum of 3 quarters · filed 2018-02-21 | $713.70M 10-K · filed 2019-02-27 | ||||
| 2016-09-30 | $161.80M 10-K · filed 2018-02-21 | $367.90M derived: sum of 2 quarters · filed 2018-02-21 | $603.40M 10-Q · filed 2017-10-25 | $708.00M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-06-30 | $206.10M 10-K · filed 2018-02-21 | $441.60M 10-Q · filed 2017-07-27 | $546.20M derived: sum of 3 quarters · filed 2018-02-21 | $1.01B derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-03-31 | $235.50M 10-K · filed 2018-02-21 | $340.10M derived: sum of 2 quarters · filed 2018-02-21 | $804.50M derived: sum of 3 quarters · filed 2018-02-21 | $903.70M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2015-12-31 | $104.60M 10-K · filed 2017-02-22 | $104.64M 10-K · filed 2016-02-25 | $569.00M derived: sum of 2 quarters · filed 2017-02-22 | $668.20M derived: sum of 3 quarters · filed 2017-02-22 | $651.60M 10-K · filed 2018-02-21 | $651.64M 10-K · filed 2016-02-25 | ||
| 2015-09-30 | $464.40M 10-K · filed 2017-02-22 | $464.43M 10-Q · filed 2015-10-27 | $563.60M derived: sum of 2 quarters · filed 2017-02-22 | $547.00M 10-Q · filed 2016-10-27 | $547.00M 10-Q · filed 2015-10-27 | $662.93M derived: sum of 4 quarters · filed 2017-02-22 | ||
| 2015-06-30 | $99.20M 10-K · filed 2017-02-22 | $99.21M 10-Q · filed 2015-07-28 | $82.60M 10-Q · filed 2016-07-28 | $82.57M 10-Q · filed 2015-07-28 | $198.53M derived: sum of 3 quarters · filed 2017-02-22 | $173.30M derived: sum of 4 quarters · filed 2017-02-22 | ||
| 2015-03-31 | -$16.60M 10-K · filed 2017-02-22 | -$16.64M 10-Q · filed 2015-04-28 | $99.33M derived: sum of 2 quarters · filed 2017-02-22 | $74.10M derived: sum of 3 quarters · filed 2017-02-22 | $185.95M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2014-12-31 | $115.94M 10-K · filed 2016-02-25 | $90.70M derived: sum of 2 quarters · filed 2016-02-25 | $202.55M derived: sum of 3 quarters · filed 2016-02-25 | $340.10M 10-K · filed 2017-02-22 | $340.07M 10-K · filed 2015-02-24 | |||
| 2014-09-30 | -$25.24M 10-K · filed 2016-02-25 | $86.61M derived: sum of 2 quarters · filed 2016-02-25 | $224.14M 10-Q · filed 2015-10-27 | $193.82M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-06-30 | $111.85M 10-K · filed 2016-02-25 | $249.38M 10-Q · filed 2015-07-28 | $219.06M derived: sum of 3 quarters · filed 2016-02-25 | $281.75M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $137.52M 10-K · filed 2016-02-25 | $107.21M derived: sum of 2 quarters · filed 2016-02-25 | $169.90M derived: sum of 3 quarters · filed 2016-02-25 | $249.76M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | -$30.31M 10-K · filed 2015-02-24 | $32.37M derived: sum of 2 quarters · filed 2015-02-24 | $112.23M derived: sum of 3 quarters · filed 2015-02-24 | $174.56M 10-K · filed 2016-02-25 | ||||
| 2013-09-30 | $62.69M 10-K · filed 2015-02-24 | $142.55M derived: sum of 2 quarters · filed 2015-02-24 | $204.87M 10-Q · filed 2014-10-28 | $288.13M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-06-30 | $79.86M 10-K · filed 2015-02-24 | $142.19M 10-Q · filed 2014-07-29 | $225.44M derived: sum of 3 quarters · filed 2015-02-24 | $303.56M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-03-31 | $62.33M 10-K · filed 2015-02-24 | $145.58M derived: sum of 2 quarters · filed 2015-02-24 | $223.69M derived: sum of 3 quarters · filed 2015-02-24 | $296.01M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2012-12-31 | $83.25M 10-K · filed 2014-02-25 | $161.37M derived: sum of 2 quarters · filed 2014-02-25 | $233.68M derived: sum of 3 quarters · filed 2014-02-25 | $304.44M 10-K · filed 2015-02-24 | ||||
| 2012-09-30 | $78.11M 10-K · filed 2014-02-25 | $150.43M derived: sum of 2 quarters · filed 2014-02-25 | $221.19M 10-Q · filed 2013-10-29 | $264.38M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-06-30 | $72.32M 10-K · filed 2014-02-25 | $143.08M 10-Q · filed 2013-07-25 | $186.26M derived: sum of 3 quarters · filed 2014-02-25 | $270.66M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-03-31 | $70.76M 10-K · filed 2014-02-25 | $113.95M derived: sum of 2 quarters · filed 2014-02-25 | $198.35M derived: sum of 3 quarters · filed 2014-02-25 | $272.24M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2011-12-31 | $43.19M 10-K · filed 2013-02-26 | $127.59M derived: sum of 2 quarters · filed 2013-02-26 | $201.48M derived: sum of 3 quarters · filed 2013-02-26 | $217.87M 10-K · filed 2014-02-25 | ||||
| 2011-09-30 | $84.40M 10-K · filed 2013-02-26 | $158.29M derived: sum of 2 quarters · filed 2013-02-26 | $174.68M 10-Q · filed 2012-11-01 | $184.22M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-06-30 | $73.89M 10-K · filed 2013-02-26 | $90.28M 10-Q · filed 2012-07-26 | $99.83M derived: sum of 3 quarters · filed 2013-02-26 | $139.56M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-03-31 | $16.39M 10-K · filed 2013-02-26 | $25.93M derived: sum of 2 quarters · filed 2013-02-26 | $65.67M derived: sum of 3 quarters · filed 2013-02-26 | $103.38M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2010-12-31 | $9.54M 10-K · filed 2012-02-28 | $49.28M derived: sum of 2 quarters · filed 2012-02-28 | $86.99M derived: sum of 3 quarters · filed 2012-02-28 | $105.92M 10-K · filed 2013-02-26 | ||||
| 2010-09-30 | $39.74M 10-K · filed 2012-02-28 | $77.44M derived: sum of 2 quarters · filed 2012-02-28 | $96.37M 10-Q · filed 2011-10-27 | |||||
| 2010-06-30 | $37.71M 10-K · filed 2012-02-28 | $56.64M derived: sum of 2 quarters · filed 2012-02-28 | ||||||
| 2010-03-31 | $18.93M 10-K · filed 2012-02-28 | |||||||
| 2009-12-31 | $19.46M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |